Blum CB et al., 2026-05-12: Systematic review (JBI methodology) of 22 studies, 17 preclinical and five clinical/population, on mebendazole in brain tumours. It concludes that mebendazole is tolerable at high oral doses but that clinical evidence does not demonstrate meaningful efficacy.
current clinical evidence does not demonstrate meaningful efficacy in brain tumour patients.
n/a
Blum CB et al., 2026-05-12: Systematic review (JBI methodology) of 22 studies, 17 preclinical and five clinical/population, on mebendazole in brain tumours. It concludes that mebendazole is tolerable at high oral doses but that clinical evidence does not demonstrate meaningful efficacy. Study type: systematic review. N=22 studies (17 preclinical, 5 clinical/population). Country: Australia (Griffith University and Bond University). Dose: reviewed across studies, not a single protocol. Funder: not stated in the abstract. Conflicts: not stated in the PubMed record. Comparator: not applicable. The review notes that efficacy was influenced by formulation, with polymorph C showing better brain penetration, and calls for comparative trials with clear formulation reporting and pharmacokinetic/biomarker analyses. Also filed as MBB-07 (claims C1, C6). Study type: review.
